Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
54.53
+0.27 (0.50%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Revenue
In the year 2025, Xenon Pharmaceuticals had annual revenue of $7.50M.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
702.66
Revenue / Employee
$20,270
Employees
370
Market Cap
5.27B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Apellis Pharmaceuticals | 1.00B |
| Caris Life Sciences | 812.03M |
| Corcept Therapeutics | 761.41M |
| TG Therapeutics | 616.29M |
| Mirum Pharmaceuticals | 521.31M |
| Ligand Pharmaceuticals | 268.09M |
| CG Oncology | 4.04M |
XENE News
- 6 days ago - Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference - Transcripts
- 9 days ago - Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting - GlobeNewsWire
- 13 days ago - Xenon to Present at Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - GlobeNewsWire
- 6 weeks ago - Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Xenon Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga